Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
Biomarkers in Barrett esophagus
Autore:
Krishnadath, KK; Reid, BJ; Wang, KK;
Indirizzi:
Mayo Clin, Div Gastroenterol & Hepatol & Internal Med, Rochester, MN 55905USA Mayo Clin Rochester MN USA 55905 l & Internal Med, Rochester, MN 55905USA Univ Washington, Fred Hutchinson Canc Inst, Div Gastrointestinal Oncol, Seattle, WA USA Univ Washington Seattle WA USA v Gastrointestinal Oncol, Seattle, WA USA
Titolo Testata:
MAYO CLINIC PROCEEDINGS
fascicolo: 4, volume: 76, anno: 2001,
pagine: 438 - 446
SICI:
0025-6196(200104)76:4<438:BIBE>2.0.ZU;2-V
Fonte:
ISI
Lingua:
ENG
Soggetto:
COMPARATIVE GENOMIC HYBRIDIZATION; ORNITHINE DECARBOXYLASE ACTIVITY; DYSPLASIA-CARCINOMA SEQUENCE; P53 PROTEIN ACCUMULATION; TUMOR-SUPPRESSOR GENES; GROWTH-FACTOR RECEPTOR; IN-SITU HYBRIDIZATION; HIGH-GRADE DYSPLASIA; NEOPLASTIC PROGRESSION; GASTROESOPHAGEAL JUNCTION;
Tipo documento:
Article
Natura:
Periodico
Settore Disciplinare:
Clinical Medicine
Life Sciences
Citazioni:
100
Recensione:
Indirizzi per estratti:
Indirizzo: Krishnadath, KK Mayo Clin, Div Gastroenterol & Hepatol & Internal Med, Rochester, MN 55905USA Mayo Clin Rochester MN USA 55905 , Rochester, MN 55905USA
Citazione:
K.K. Krishnadath et al., "Biomarkers in Barrett esophagus", MAYO CLIN P, 76(4), 2001, pp. 438-446

Abstract

Barrett esophagus is a premalignant condition that may progress to adenocarcinoma, The risk of developing cancer has been estimated to be approximately 1 in 250 patient-years of observation; however, there appear to be subsets of patients at much higher risk. Risk stratification has previously beendetermined by histological identification of dysplasia, Several new biomarkers are being tested to help clinicians better determine the risk of cancer development, Although none of these biomarkers has been proven in a prospective study to predict the onset of cancer, they have been correlated withcancer development. Most of these are factors that have been associated with cancer development in other organs. These include assessment of cell proliferation, expression of cyclooxygenase 2, growth factors and oncogenes, secretory factors, cell cycle proteins, adhesion molecules, and aneuploidy and other genetic abnormalities. In addition to their role as potential cancer biomarkers, these factors have increasingly been reported as surrogate markers to monitor the effectiveness of conservative treatments for Barrett esophagus, In this article, biological markers are reviewed for their relevance in Barrett esophagus, Although most biological markers need to be evaluated further and, for most, prospective follow-up studies are lacking, at present abnormal ploidy status, P16 and P53 gene abnormalities, or allelic losses are the most extensively documented.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 25/01/21 alle ore 16:14:41